Researchers from Shaperon Inc. presented positive preclinical data for their clinical-stage candidate, sodium taurodeoxycholate (HY-209), demonstrating its therapeutic potential for atopic dermatitis.
Hangzhou Innogate Pharma Co. Ltd. has divulged new NLRP3 inflammasome inhibitors reported to be useful for the treatment of inflammation, cancer, infections and metabolic, respiratory, liver, kidney and autoimmune diseases, among other disorders.
